F8 and hemophilia A: With emicizumab, people with hemophilia A now have an effective and tolerable subcutaneous treatment option, offering a stable level of bleed prevention over time, in contrast to the peaks and troughs of FVIII replacement therapy, and has the added benefit of less burdensome treatment regimens and improved QoL.